We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00909051
First Posted: May 27, 2009
Last Update Posted: January 19, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bayer
  Purpose
Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

Condition Intervention
Diabetes Mellitus Drug: Acarbose (Glucobay, BAYG5421)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI) [ Time Frame: During observation period of three months ]

Enrollment: 15729
Study Start Date: March 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Acarbose (Glucobay, BAYG5421)
Patients with diabetes type 2 newly treated with Glucobay

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
  • Patients with untreated or pretreated diabetes mellitus type 2
  • No Glucobay® intake within the last 3 months before documentation of initial visit
  • Exclusion Criteria: contraindication stated in the local Glucobay® product information; warnings and precautions must be considered.
Criteria

Inclusion Criteria:

  • Patients with untreated or pretreated diabetes mellitus or patients for which acarbose is indicated and without acarbose treatment within the last three months before study inclusion. The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00909051


Locations
Algeria
Many Locations, Algeria
Bosnia and Herzegovina
Many Locations, Bosnia and Herzegovina
Cambodia
Many Locations, Cambodia
China
Many Locations, China
Hong Kong
Many Locations, Hong Kong
India
Many Locations, India
Indonesia
Many Locations, Indonesia
Korea, Republic of
Many Locations, Korea, Republic of
Malaysia
Many Locations, Malaysia
Moldova, Republic of
Many Locations, Moldova, Republic of
Pakistan
Many Locations, Pakistan
Philippines
Many Locations, Philippines
Russian Federation
Many Locations, Russian Federation
Singapore
Many Locations, Singapore
Thailand
Many Locations, Thailand
Vietnam
Many Locations, Vietnam
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Medical Affairs Therapeutic Area Head, Bayer HealthCare AG
ClinicalTrials.gov Identifier: NCT00909051     History of Changes
Other Study ID Numbers: 14284
GB0701 ( Other Identifier: Company internal )
First Submitted: May 26, 2009
First Posted: May 27, 2009
Last Update Posted: January 19, 2012
Last Verified: January 2012

Keywords provided by Bayer:
Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Acarbose
Glycoside Hydrolase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs